National Center for Accelerated Innovations (NCAI)
The Office of Translation and Innovation will host an information session on the National Center for Accelerated Innovations (NCAI) program, including details on the current RFA, led by Mark Low, Managing Director for the NCAI-Cleveland Clinic and Mark Chance, Vice Dean for Research in the CWRU School of Medicine.
The information session will be held next Monday, January 26 from 12n - 1pm in BRB 932.
All interested investigators are encouraged to attend. If you are coming from outside the School of Medicine, please stop by the security desk on the ground floor of the Biomedical Research Building and they will give you access to the elevators.
Drs. Low and Chance, among others, will be on hand to help answer any questions you have about this innovations program. The NCAI is currently running it's third funding cycle RFA. This regional funding opportunity is a great chance to move your translational research project to the next level.
Letter of Intent deadline is February 10, 2015
Please RSVP to Anne DeChant or to email@example.com
For more information on the RFA visit the NCAI-CC website.
Foundation Fighting Blindness and Harrington Discovery Institute
Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.
• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
• Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.
Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.
For more information about Foundation Fighting Blindness visit the Fighting Blindness website.
Ohio Third Frontier (OTF), Ohio Development Services Agency
The goal of the Ohio Third Frontier Technology Validation and Start-Up Fund (TVSF) is to increase economic growth in Ohio through start-up companies that commercialize technologies developed by Ohio institutions of higher education and other Ohio not-for-profit research institutions. Two separate mechanisms have been set up to achieve these goals:
Phase 1 –Technology Validation The specific objectives of this phase are as follows:
• To generate the proof needed to move technology to the point that it is either ready to be licensed by an Ohio start-up company or otherwise deemed unfeasible for commercialization.
• To fund validation activities, such as prototyping, demonstrations, and assessment of critical failure points in subsequent development, scale-up, and commercialization.
Phase 2 – Start-Up Funds The specific objectives of this phase are as follows:
• To support Ohio start-up companies that have licensed technology developed at Ohio research institutions during the critical early life of the company, and accelerate the time to market of this technology.
• To generate the proof needed to either commercialize the technology or move the technology to the point where additional funds needed for commercialization can be raised.
• To fund activities in order to generate the needed proof.
The TVSF will support technology that falls within the following areas: Advanced Materials related to advanced polymers, ceramics, composites, carbon fibers and nanotubes and specialty metals and alloys; Aeropropulsion Power Management; Agribusiness and Food Processing; Fuel Cells and Energy Storage; Medical Technology related to imaging, surgical instruments/equipment, implant devices, and regenerative medicine; Software Applications for business and healthcare; Sensing and Automation Technologies; Situational Awareness and Surveillance Systems; Solar Photovoltaics; and Shale.
Potential CWRU Applicants - Contact:
Michael Haag, MS, MBA, Executive Director, Technology Management, 216-368-6106 or firstname.lastname@example.org.
For more information on the TVSF visit the Ohio Third Frontier website.
Case-Coulter Translational Research Partnership (CCTRP)
This is the fourth year of the second phase of the Case-Coulter Translational Research Partnership to support collaborative translational research projects that address unmet or poorly met clinical needs. The CCTRP seeks to reduce the market risk of promising new clinical products arising from the research programs of BME and other Case faculty. Successful projects will thus often focus on the development of prototype products, building relationships with companies, performing clinical feasibility studies, obtaining regulatory approval, and other activities that companies or business experts indicate are the essential last steps before a license can be negotiated or a startup launched. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a three- to five-year horizon. Because the goals of all Coulter projects are to reduce market risk, all proposals are expected to reflect genuine business input, and all projects must include a “business advisor” as an important member of the decision making team.
Awards up to $200,000 will be considered if well justified.
Letter of Intent Deadline: February 13, 2015
For more information visit the BME website.
Shipping Abroad in Compliance with Export Regulations
The federal export control laws can apply when regulated items are being shipped abroad. Before shipping a device, materials, or other items abroad, CWRU personnel should contact either the Environmental Health and Safety Office or the Compliance Office so that an employee trained in export compliance can determine whether an export license is needed prior to making the shipment.
These are the steps that all CWRU researchers should follow when planning to make an outgoing international shipment of items or materials:
If you have questions on how the export regulations impact specific international shipments, contact the Compliance Office: Lisa Palazzo, Director of Export Control and Privacy Management, at 368-5791, or Boyd Kumher, University Chief Compliance, Export Control and Privacy Management Officer, at 368-0833; or email email@example.com.
- The CWRU Principal Investigator works with the CWRU Technology Transfer Office (“TTO”) to determine whether a Material Transfer Agreement (“MTA”) is needed prior to the shipment. The CWRU PI initiates this by submitting a completed MTA Review Form found at https://research.case.edu/forms.cfm#tech_mgt.
- If the Technology Transfer Office determines that an MTA is needed between CWRU and the overseas organization to receive the items or materials, the Principal Investigator and TTO work together to put it in place. Once the MTA is completed and signed by CWRU and the recipient organization, the Technology Transfer Office will forward a copy of the final contract to the PI. The PI should keep a copy of the final MTA for easy reference. Note that MTAs not only help to ensure compliance with the federal export laws, but they also protect investigators’ intellectual property rights.
- Before making the shipment overseas, the PI should contact the CWRU Environmental Health and Safety Office. This step is necessary so that the Environmental Health and Safety Office can analyze the contents of the shipment in light of the export regulations and determine whether the shipment can proceed immediately, or whether federal pre-authorization is needed. If the Technology Transfer Office determined that an MTA was needed, then the PI should provide Environmental Health and Safety with a copy of the signed MTA so that it can match the requested shipment with the formal contract.
For more information on the export control regulations, including the full text of CWRU’s Export Control Policy Statement, visit http:www.case.edu/compliance/exportcontrol/.
Questions regarding Material Transfer Agreements (MTAs), should be addressed to Andrew Jarrell in the Technology Transfer Office, Andrew.firstname.lastname@example.org, 368-1401.
If you have news or information that you wish to have included in this
update, please send it via e-mail to Tracy Wilson-Holden at
email@example.com no later than
5 pm on the Monday of the week that the update is to be distributed. If you
know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe
to Case Research News, email your request to Tora Williams at
Please note: At the time of this transmission, all links functioned.
However, Case Research News cannot guarantee that the information will not move or be